Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Basis of Presentation and Summary of Significant Accounting Policies

Schedule of customers representing 10% or more of revenues

	Years Ended
	December 31,
	2015		2014		2013
AmerisourceBergen Drug Corporation	25	%	34	%	41	%
Takeda Pharmaceuticals Company Limited	12	%	11	%	11	%
McKesson Corporation	11	%	21	%	24	%
Cardinal Health, Inc.	<10	%	15	%	16	%

Schedule of customers representing greater than 10% of accounts receivable balances

	December 31,
	2015		2014
AmerisourceBergen Drug Corporation	43	%	45	%
McKesson Corporation	<10	%	12	%

Schedule of property, plant and equipment estimated useful lives

	Useful Life
Buildings and improvements	15 - 40 Years
Computer equipment and software	5 Years
Furniture and fixtures	5 Years
Leasehold improvements	Lesser of Lease or Asset Life
Laboratory and production equipment	5 Years
Land improvements	10 Years

Analysis of U.S. product sales allowances and accruals

Our product revenues were offset by provisions for allowances and accruals as follows (in thousands):

	Years Ended December 31,
	2015		2014		2013
Gross U.S. product sales	$	561,255	$	190,512	$	120,195
Provision for U.S. product sales allowances and accruals:
Contractual adjustments		161,665		73,262		48,433
Governmental rebates		57,774		7,252		70
Total provision for U.S. product sales allowances and accruals		219,439		80,514		48,503
U.S. product sales, net	$	341,816	$	109,998	$	71,692

Schedule of components of basic and diluted net income (loss) per share

The components of basic and diluted net income (loss) per share for 2015, 2014 and 2013 were as follows (in thousands, except per share data):

	Years Ended December 31,
	2015		2014		2013
Net income (loss) - basic	$	32,779	$	135,817	$	(9,602)
Dilutive effect of convertible 2.5% notes		—		1,654		—
Net income (loss) - diluted	$	32,779	$	137,471	$	(9,602)
Weighted average common shares outstanding		31,471		22,416		21,703
Effect of dilutive securities:
Warrants		2,466		—		—
Stock options and RSUs		1,371		520		—
Convertible 2.5% notes		—		2,289		—
Shares used in calculating dilutive net income (loss) per share		35,308		25,225		21,703
Net income (loss) per share:
Basic	$	1.04	$	6.06	$	(0.44)
Diluted	$	0.93	$	5.45	$	(0.44)

Schedule of anti-dilutive securities excluded from computation of diluted net loss per share

The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs, the exercise of warrants (prior to consideration of the treasury stock method), and the conversion of the 2.5% Convertible Notes, which were excluded from our computation of diluted net income (loss) per share because their inclusion would have been anti-dilutive (in thousands):

	Years Ended December 31,
	2015	2014	2013
Options to purchase shares of common stock	1,619	2,708	2,820
Shares of common stock issuable upon the vesting of RSUs	167	322	465
Warrants	—	7,382	—
Convertible 2.5% notes	7,382	—	—
Total	9,168	10,412	3,285